Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 6/20 | 0.58 |
| ▸ | CA1 | P00915 | 6/20 | 0.58 |
| ▸ | CA2 | P00918 | 6/20 | 0.58 |
| ▸ | CA9 | Q16790 | 6/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14571199 | 1.00 | TDP1 (0.73) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL12772839 | 1.00 | TDP1 (0.73) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL21996829 | 1.00 | TDP1 (0.73) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL691053 | 0.98 | TDP1 (0.70) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL694362 | 0.94 | TDP1 (0.65) | TDP1MAOAMAOBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL30183864 | 0.92 | TDP1 (0.62) | TDP1MAOAMAOBMEN1KMT2A | |
| Bromide SCHEMBL17818451 | 0.92 | TDP1 (0.62) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL136815 | 0.92 | TDP1 (0.85) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL3025184 | 0.92 | TDP1 (0.85) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL137629 | 0.92 | TDP1 (0.85) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4166557-B1 | INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2026-05-06 | — | — | EP | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| US-12441733-B2 | Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2025-10-14 | — | — | US | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-119775346-A | E3 ubiquitin ligase ligand compound and application thereof | 天津医科大学 | 2025-04-08 | — | — | CN | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250064968-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4469090-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | Genentech Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4467549-A2 | INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | Novartis AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20210002285-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | NOVARTIS PHARMA AG (CH) | 2021-01-07 | — | — | US | disclosed |
| CN-111936498-A | N- (3- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) phenyl) benzamide derivatives | 诺华股份有限公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2019186343-A1 | N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2019-10-03 | — | — | WO | disclosed |
| US-9284283-B2 | Macrocyclic compounds for modulating IL-17 | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2809660-B1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORP (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION | 2015-01-01 | — | — | US | disclosed |
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION | 2015-01-01 | — | — | US | disclosed |
| WO-2013116682-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20110092601-A1 | LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | IL17A, IL15, IL2 | TDP1 4706/4885MAOA 3928/4885MAOB 3294/4885 |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | TDP1 2757/4885MAOA 4135/4885MAOB 3220/4885 |
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TDP1 236/4885MAOA 2771/4885MAOB 2743/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TDP1 236/4885MAOA 2771/4885MAOB 2743/4885 |
| US-20250064968-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | LGMN, B2M, HNMT | TDP1 2839/4885MAOA 3433/4885MAOB 3726/4885 |
| US-20110092601-A1 | LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | KDM4E, KDM3A, KDM2A | TDP1 158/4885MAOA 836/4885MAOB 557/4885 |
| US-12441733-B2 | Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors | BTK, ABL1, LYN | TDP1 205/4885MAOA 2234/4885MAOB 1390/4885 |
| US-20210002285-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | PAH, PARK7, PKD1 | TDP1 2013/4885MAOA 1058/4885MAOB 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.